ArticleFrontiers in immunology2026
Chemotherapy driven alterations in NK cell receptors and ligands in high grade serous ovarian cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Combination approaches are being explored to improve immunotherapy efficacy, yet the immunomodulatory effects of chemotherapy on NK cell receptors and their ligands remain unexplored in high-grade serous ovarian cancer (HGSOC). Therefore, understanding chemotherapy-induced immune modulation is essential in HGSOC. Methods: Immune profiling was conducted on clinical specimens from 33 chemo-naïve patients undergoing primary debulking surgery (PDS), 57 chemotherapy-treated patients undergoing interval debulking surgery (IDS), and 17 patients in the IDS group were followed during chemotherapy cycles. Immune profiling was carried out using flow cytometry, Procartaplex immunoassay, and ELISA. Blood samples were collected from 50 age- and gender-matched healthy participants for comparison. Results: Primary investigation on follow-up patients reveals chemotherapy-mediated immune modulation on NK cell subsets. This was further validated in the chemo-treated surgical cohort. The Natural Cytotoxicity Receptors (NCRs) were downregulated on NK cells in chemo-naïve surgical cohorts. The NCR group of receptors was normalized to a level comparable to that in healthy controls in the chemotherapy-treated surgical cohort, due to reduced soluble ligands. Surface MICA expression was also increased (p = 0.0466) on EpCAM+ cells in the chemo-treated surgical cohort compared to the chemo-naïve surgical cohort, while NKG2D+ immune cells were reduced in both surgical cohorts compared to healthy controls. Moreover, proinflammatory cytokines IL-2 (p = 0.0001) and TNF-α (p = 0.0442) were reduced in the chemotherapy-treated surgical cohort, while intracellular levels of dual perforin and granzyme were elevated in the chemo-treated group, which may enhance cytolytic potential. High surface expressions of HLA-E, MIC-B, and LLT-1 ligands were associated with improved progression-free survival. Conclusions: Our findings highlight the broad immunomodulatory effects of chemotherapy on NK cell receptors, ligands, and cytokines, which may offer insights for combination therapies in HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.